Prognostic value of the Scottish inflammatory prognostic score in ST-Segment elevation myocardial infarction.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-04-01 Epub Date: 2026-04-15 DOI:10.1080/17520363.2026.2659655

Bektas Murat, Selda Murat, Fatih Aydin

{"title":"Prognostic value of the Scottish inflammatory prognostic score in ST-Segment elevation myocardial infarction.","authors":"Bektas Murat, Selda Murat, Fatih Aydin","doi":"10.1080/17520363.2026.2659655","DOIUrl":null,"url":null,"abstract":"Aims: The Scottish Inflammatory Prognostic Score (SIPS), has emerged as a simple inflammation-based biomarker; however, its prognostic value in ST-segment elevation myocardial infarction (STEMI) has not been well established. This study aimed to evaluate the prognostic utility of SIPS for predicting long-term major adverse cardiac events (MACE) in STEMI patients.Materials and methods: We included 829 STEMI patients between 2018 and 2024. SIPS was categorized as low (0 points), moderate (1 point), or high risk (2 points). The primary endpoint was time-to-first MACE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, stroke, or cardiovascular hospitalization, using Cox proportional hazards models, competing risk analysis, and measures of incremental discrimination.Results: During follow-up, MACE occurred in 293 patients (35.3%), with a stepwise increase across SIPS categories (23%, 40%, and 63%; p < 0.001). SIPS independently predicted MACE in multivariable analysis (HR per point: 1.62, 95% CI 1.35-1.94; p < 0.001). Discriminative performance was moderate (AUC = 0.655). SIPS remained independently associated with MACE in hierarchical multivariable and competing risk analyses and provided incremental prognostic value beyond clinical predictors.Conclusion: SIPS is an independent predictor of long-term MACE in STEMI patients after PPCI and may serve as a simple and cost-effective tool for early risk stratification.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"275-284"},"PeriodicalIF":2.1000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2659655","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The Scottish Inflammatory Prognostic Score (SIPS), has emerged as a simple inflammation-based biomarker; however, its prognostic value in ST-segment elevation myocardial infarction (STEMI) has not been well established. This study aimed to evaluate the prognostic utility of SIPS for predicting long-term major adverse cardiac events (MACE) in STEMI patients.

Materials and methods: We included 829 STEMI patients between 2018 and 2024. SIPS was categorized as low (0 points), moderate (1 point), or high risk (2 points). The primary endpoint was time-to-first MACE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, stroke, or cardiovascular hospitalization, using Cox proportional hazards models, competing risk analysis, and measures of incremental discrimination.

Results: During follow-up, MACE occurred in 293 patients (35.3%), with a stepwise increase across SIPS categories (23%, 40%, and 63%; p < 0.001). SIPS independently predicted MACE in multivariable analysis (HR per point: 1.62, 95% CI 1.35-1.94; p < 0.001). Discriminative performance was moderate (AUC = 0.655). SIPS remained independently associated with MACE in hierarchical multivariable and competing risk analyses and provided incremental prognostic value beyond clinical predictors.

Conclusion: SIPS is an independent predictor of long-term MACE in STEMI patients after PPCI and may serve as a simple and cost-effective tool for early risk stratification.

查看原文本刊更多论文

苏格兰炎性预后评分在st段抬高型心肌梗死中的预后价值。

目的：苏格兰炎症预后评分（SIPS）已经成为一种简单的基于炎症的生物标志物；然而，其在st段抬高型心肌梗死（STEMI）中的预后价值尚未得到很好的确定。本研究旨在评估SIPS预测STEMI患者长期主要不良心脏事件（MACE）的预后效用。材料和方法：我们在2018年至2024年间纳入了829例STEMI患者。SIPS分为低危（0分）、中度（1分）、高危（2分）。主要终点是首次MACE时间，定义为全因死亡率、非致死性心肌梗死、卒中或心血管住院的综合，使用Cox比例风险模型、竞争风险分析和增量歧视措施。结果：随访期间，有293例（35.3%）患者发生MACE，在SIPS分类中逐步增加（23%，40%和63%）；结论：SIPS是STEMI患者PPCI后长期MACE的独立预测因子，可作为早期风险分层的简单且经济有效的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.